Parker Institute for Cancer Immunotherapy
Coltin Krauss is Senior Director of Financial Planning & Analysis at the Parker Institute for Cancer Immunotherapy (PICI), having worked previously as a project budgeting consultant for the organization. In his expanded role, he will concentrate on corporate-wide strategic financial planning, budgeting, analysis and reporting.
Before joining PICI, Coltin was a finance consultant at Myovant Sciences, where he helped launch their first product, ORGOVYX, a prescription medicine for advanced prostate cancer. Before that, he served in various R&D finance roles
at Genentech/Roche Group.
This person is not in any offices
Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) is radically changing the way cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, the San Francisco-based nonprofit is an unprecedented collaboration between the country's leading immunotherapy researchers and cancer centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center.